Investment Thesis — DaVita Inc.
The market misprices DaVita by fixating on its historical negative book value and perceived balance sheet weakness, overlooking its robust forward earnings potential and recent positive regulatory tailwinds. The deeply discounted forward P/E and P/S multiples fail to reflect the stability of its essential healthcare services and its ability to generate significant free cash flow, which is now de-risked by recent developments.
Catalysts
- Sustained favorable Medicare Advantage reimbursement rates
- Successful deleveraging and improved capital structure
- Expansion into higher-margin integrated kidney care services
Risk Factors
- Adverse changes in Medicare/Medicaid reimbursement rates
- Significant litigation or regulatory penalties
- Inability to effectively manage its highly leveraged balance sheet and negative equity
Key Debates
Commercial mix improves, accelerating revenue growth above 2.5% by H2.
Short squeeze drives DVA shares past $168.67 by Q4.
DVA's 10.9x P/E expands to 13x by Q1 2025 as growth stabilizes.